---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Ibritumomab Tiuxetan - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/ibritumomabtiuxetan
version: v1
---

# Ibritumomab Tiuxetan - NCI

# Ibritumomab Tiuxetan

Placeholder slot

(ih-brih-TOO-moh-mab ty-UK-seh-tan)

This page contains brief information about ibritumomab tiuxetan and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Zevalin

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ccf29429-bf8e-4cce-bd12-1de56853fc5b&audience=consumer)

## Use in Cancer

Ibritumomab tiuxetan is approved to treat:

- **[B-cell](/Common/PopUps/popDefinition.aspx?id=444967&version=Patient&language=English) [follicular non-Hodgkin lymphoma](/Common/PopUps/popDefinition.aspx?id=428287&version=Patient&language=English)**. It is used in adults:
- With [relapsed](/Common/PopUps/popDefinition.aspx?id=45866&version=Patient&language=English) or [refractory](/Common/PopUps/popDefinition.aspx?id=45863&version=Patient&language=English) [low-grade](/Common/PopUps/popDefinition.aspx?id=45757&version=Patient&language=English) disease.
- Who are having a [complete](/Common/PopUps/popDefinition.aspx?id=45652&version=Patient&language=English) or [partial response](/Common/PopUps/popDefinition.aspx?id=45819&version=Patient&language=English) to [first-line](/Common/PopUps/popDefinition.aspx?id=346494&version=Patient&language=English) [chemotherapy](/Common/PopUps/popDefinition.aspx?id=45214&version=Patient&language=English).

Ibritumomab tiuxetan is also being studied in the treatment of other types of [cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=Patient&language=English).

## More About Ibritumomab Tiuxetan

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/43080) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Ibritumomab Tiuxetan](https://medlineplus.gov/druginfo/meds/a609012.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

[Targeted Cancer Therapies](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Ibritumomab Tiuxetan](https://www.cancer.gov/research/participate/clinical-trials/intervention/C29981) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
